Literature DB >> 15492467

Cytochrome c release from oridonin-treated apoptotic A375-S2 cells is dependent on p53 and extracellular signal-regulated kinase activation.

Chun-Ling Zhang1, Li-Jun Wu, Hai-Jun Zuo, Shin-ichi Tashiro, Satoshi Onodera, Takashi Ikejima.   

Abstract

We have reported that oridonin isolated from Rabdosia rubescens induces apoptosis of human melanoma A375-S2 cells within 12 h. In this study, TUNEL assay and flow cytometric analysis also indicate that one of the causes of A375-S2 cell death induced by oridonin was apoptosis. The cell death was preceded by the release of cytochrome c from the mitochondria. Twelve hours after treatment with oridonin, the ratio of Bax/Bcl-xL protein expression was increased and release of cytochrome c was decreased by an extracellular signal-regulated kinase (ERK) MAPK inhibitor (PD98059) and a phosphoinositide 3-kinases (PI3-K) inhibitor (wortmannin). A mitochondrial permeability transition (MPT) inhibitor, decylubiquinone, suppressed the release of cytochrome c without affecting Bax expression. The activation of p53 by oridonin was also blocked by wortmannin. In addtion, PD98059 and wortmannin significantly decreased oridonin-induced DNA fragmentation, but the p38 MAPK inhibitor (SB203580) did not after DNA fragmentation. Oridonin induced A375-S2 cell apoptosis by activating parallel p53 and ERK pathways, increasing the ratio of Bax/Bcl-xL protein expression, and promoting the release of cytochrome c into the cytosol, resulting in apoptotic cell death.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15492467     DOI: 10.1254/jphs.fpj04008x

Source DB:  PubMed          Journal:  J Pharmacol Sci        ISSN: 1347-8613            Impact factor:   3.337


  19 in total

1.  Oridonin, a diterpenoid extracted from medicinal herbs, targets AML1-ETO fusion protein and shows potent antitumor activity with low adverse effects on t(8;21) leukemia in vitro and in vivo.

Authors:  Guang-Biao Zhou; Hui Kang; Lan Wang; Li Gao; Ping Liu; Jun Xie; Feng-Xiang Zhang; Xiang-Qin Weng; Zhi-Xiang Shen; Jue Chen; Long-Jun Gu; Ming Yan; Dong-Er Zhang; Sai-Juan Chen; Zhen-Yi Wang; Zhu Chen
Journal:  Blood       Date:  2006-12-29       Impact factor: 22.113

2.  Regio- and Stereospecific Synthesis of Oridonin D-Ring Aziridinated Analogues for the Treatment of Triple-Negative Breast Cancer via Mediated Irreversible Covalent Warheads.

Authors:  Ye Ding; Dengfeng Li; Chunyong Ding; Pingyuan Wang; Zhiqing Liu; Eric A Wold; Na Ye; Haiying Chen; Mark A White; Qiang Shen; Jia Zhou
Journal:  J Med Chem       Date:  2018-03-20       Impact factor: 7.446

3.  Celastrus orbiculatus extract inhibits tumor angiogenesis by targeting vascular endothelial growth factor signaling pathway and shows potent antitumor activity in hepatocarcinomas in Vitro and in Vivo.

Authors:  Ya-yun Qian; Hua Zhang; Ying Hou; Lin Yuan; Guo-qing Li; Shi-yu Guo; Tadashi Hisamits; Yan-qing Liu
Journal:  Chin J Integr Med       Date:  2011-07-30       Impact factor: 1.978

4.  Genomic and in vivo evidence of synergy of a herbal extract compared to its most active ingredient: Rabdosia rubescens vs. oridonin.

Authors:  Angela M Wong; Yanjung Zhang; Kelly Kesler; Max Deng; Lucas Burhenn; David Wang; Aune Moro; Zhaoping Li; David Heber
Journal:  Exp Ther Med       Date:  2010-09-01       Impact factor: 2.447

5.  Oridonin in combination with imatinib exerts synergetic anti-leukemia effect in Ph+ acute lymphoblastic leukemia cells in vitro by inhibiting activation of LYN/mTOR signaling pathway.

Authors:  Yong Guo; Qingqing Shan; Yuping Gong; Juan Lin; Xi Yang; Ruiqing Zhou
Journal:  Cancer Biol Ther       Date:  2012-08-16       Impact factor: 4.742

6.  Novel nitrogen-enriched oridonin analogues with thiazole-fused A-ring: protecting group-free synthesis, enhanced anticancer profile, and improved aqueous solubility.

Authors:  Chunyong Ding; Yusong Zhang; Haijun Chen; Zhengduo Yang; Christopher Wild; Lili Chu; Huiling Liu; Qiang Shen; Jia Zhou
Journal:  J Med Chem       Date:  2013-06-19       Impact factor: 7.446

Review 7.  Oridonin: targeting programmed cell death pathways as an anti-tumour agent.

Authors:  Z Liu; L Ouyang; H Peng; W-Z Zhang
Journal:  Cell Prolif       Date:  2012-12       Impact factor: 6.831

8.  The cell death of C6 astrocytoma cells induced by oridonin and its mechanism.

Authors:  Bo Yin; Hansong Sheng; Jian Lin; Hui Zhou; Nu Zhang
Journal:  Int J Clin Exp Pathol       Date:  2012-07-29

9.  Anti-cancer natural products isolated from chinese medicinal herbs.

Authors:  Wen Tan; Jinjian Lu; Mingqing Huang; Yingbo Li; Meiwan Chen; Guosheng Wu; Jian Gong; Zhangfeng Zhong; Zengtao Xu; Yuanye Dang; Jiajie Guo; Xiuping Chen; Yitao Wang
Journal:  Chin Med       Date:  2011-07-22       Impact factor: 5.455

Review 10.  Oridonin and its derivatives for cancer treatment and overcoming therapeutic resistance.

Authors:  Xi Liu; Jimin Xu; Jia Zhou; Qiang Shen
Journal:  Genes Dis       Date:  2020-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.